CAN-FITE BIOPHARMA LTD. 9/30/2013 Unaudited Pro Forma Interim Consolidated Balance Sheet $1 = NIS 3.537 Convenience translation Shares and Into options issuance Proforma data U.S. dollars. September 30, September 30

CAN-FITE BIOPHARMA LTD. 9/30/2013 Unaudited Pro Forma Interim Consolidated Balance Sheet $1 = NIS 3.537 Convenience translation Shares and Into options issuance Proforma data U.S. dollars. September 30, September 30, September 30, 2013 2013 2013 Unaudited Unaudited Unaudited NIS in thousands NIS in thousands NIS in thousands In thousands ASSETS CURRENT ASSETS: Cash and cash equivalents 9,673 21,292 30,965 8,755 Accounts receivable 1,615 1,615 457 11,288 21,292 32,580 9,211 NON-CURRENT ASSETS: Property, plant and equipment, net 157 157 44 11,445 21,292 32,737 9,256 LIABILITIES AND EQUITY CURRENT LIABILITIES: Trade payables 2,046 1,154 3,200 905 Other accounts payable 2,502 2,502 707 Options exercisable into shares (series 6) 149 149 42 Options exercisable into shares (series 7) 159 159 45 Options exercisable into shares (series 8) 308 308 87 5,164 1,154 6,318 1,786 NON-CURRENT LIABILITIES: Options exercisable into shares (series 7) - - Employee benefit liabilities, net 67 67 19 5,231 1,154 6,385 1,805 EQUITY (DEFICIENCY) ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: Share capital 3,568 459 4,027 1,139 Share premium 250,782 16,781 267,563 75,647 Capital reserve from share-based payment transactions 15,561 159 15,720 4,444 Options exercisable into shares (series 9) 669 669 189 Options exercisable into shares (series 10) 3,178 3,178 899 Options exercisable into shares (series 11) 3,066 3,066 867 Options exercisable into shares (series 12) 2,739 2,739 774 Treasury shares (3,628 ) (3,628 ) (1,026 ) Adjustments arising from translating financial statements of foreign operations (117 ) (117 ) (33 ) Accumulated deficit (269,371 ) (269,371 ) (76,158 ) 3,708 20,138 23,846 6,742 Non-controlling interests 2,506 2,506 709 Total equity 6,214 20,138 26,352 7,450 11,445 21,292 32,737 9,256